1 day ago · In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year ...

Jan 28, 2025 · Novo Nordisk has reported weight loss effects of up to 22% in patients who received a weekly subcutaneous dose of its next-generation weight loss drug, amycretin, over the course of 36 weeks. These topline results show early potential for the drug candidate to surpass the efficacy of Eli Lilly’s Zepbound (tirzepatide), one of its major ...

Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.

1 day ago · Details about its next-generation weight loss drugs CagriSema and amycretin are also in focus. It's been a rocky few months for Novo Nordisk . 24/7 New York news stream: Watch NBC 4 free wherever ...

Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...

Dec 20, 2024 · Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Dec 20, 2024 · Novo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it released data from a new weight loss drug trial. The new drug, CagriSema, led patients to lose 22.7% of their body...

Sep 11, 2024 · Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potential...

Sep 23, 2024 · An experimental new pill from Novo Nordisk, called amycretin, could cause substantial weight loss in people with obesity. The once-daily oral medication is in the same class as the blockbuster obesity and diabetes medications, Ozempic and Mounjaro.

Mar 7, 2024 · An experimental pill developed by Novo Nordisk helped obese people lose 13% of their body weight after three months of treatment in a small clinical trial, the company said Thursday, in a result one analyst described as among the best of …